https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd/
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD | GSK
GSK announces positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) in adults with COPD.
phase iii trial
https://www.cochrane.org/ms/evidence/CD010834_mepolizumab-reslizumab-or-benralizumab-people-already-taking-inhaled-steroids-and-long-acting-beta-2
Mepolizumab, reslizumab atau benralizumab untuk orang yang sudah mengambil sedutan steroid dan...
untuk orang
https://pmc.ncbi.nlm.nih.gov/articles/PMC12025051/
Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment...
Eosinophilic granulomatosis with polyangiitis (EGPA) is a necrotizing vasculitis characterized by extravascular granulomas and eosinophilia in both blood and...
https://pmc.ncbi.nlm.nih.gov/articles/PMC10131245/
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES...
Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES...
https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-improved-asthma-control-in-patients-uncontrolled-on-xolair-omalizumab/
Nucala (mepolizumab) improved asthma control in patients uncontrolled on Xolair (omalizumab) | GSK
Positive clinical study outcomes observed for severe eosinophilic asthma patients uncontrolled on omalizumab
asthma controlin patients
https://www.cochrane.org/es/evidence/CD010834_mepolizumab-reslizumab-or-benralizumab-people-already-taking-inhaled-steroids-and-long-acting-beta-2
Mepolizumab, reslizumab o benralizumab para personas que ya toman corticosteroides y agonistas...
para personas
https://www.medlineplus.gov/druginfo/meds/a615058.html
Mepolizumab Injection: MedlinePlus Drug Information
Mepolizumab Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
mepolizumabinjectionmedlineplusdruginformation
https://www.cochrane.org/ms/evidence/CD013432_mepolizumab-or-benralizumab-people-chronic-obstructive-pulmonary-disease-copd
Mepolizumab atau benralizumab untuk orang dengan penyakit kronik paru-paru obstruktif (COPD) |...
untuk orangmepolizumabbenralizumab
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-ats-on-treatment-effect-of-nucala-mepolizumab-in-severe-asthma-according-to-blood-eosinophil-level/
GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to...
GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase IIIb MUSCA study
https://www.elsevier.es/en-revista-acta-otorrinolaringologica-espanola-402-estadisticas-evaluating-mepolizumab-dupilumab-for-severe-S2173573526000086
Evaluating mepolizumab and dupilumab for severe chronic rhinosinusitis with nasal polyps: insights...
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-in-europe-for-novel-anti-il5-biological-nucala-mepolizumab-for-the-treatment-of-patients-with-severe-refractory-eosinophilic-asthma/
GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for...
GSK today announced that the CHMP of EMA issued a positive opinion recommending marketing authorisation for mepolizumab
https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-treatment-of-chronic-obstructive-pulmonary-disease/
Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary...
Nucala is the only monthly biologic studied in a wide COPD population with an eosinophilic phenotype.
https://www.gsk.com/en-gb/media/press-releases/gsk-nucala-mepolizumab-filings-accepted-by-european-medicines-agency-for-three-additional-eosinophil-driven-diseases/
GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional...
If approved in the EU, Nucala would be the only treatment indicated for four eosinophil-driven diseases.
european medicines agency
https://www.muni.cz/vyzkum/publikace/2492621
The effect of mepolizumab dosage form on treatment outcomes in severe asthma | Masarykova...
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-positive-phase-iii-study-investigating-mepolizumab-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis-egpa/
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients...
GSK announces NEJM publication of phase III study investigating mepolizumab in patients with EGPA
phase iii study
https://www.gsk.com/en-gb/media/press-releases/nucala-application-for-copd-accepted-for-review-in-china/
Nucala (mepolizumab) application for COPD accepted for review in China | GSK
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
in chinanucalamepolizumabapplicationcopd
https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-in-china/
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease...
Nucala is the first and only monthly biologic approved in China studied in a wide COPD population
https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options/
Nucala (mepolizumab) gains FDA approval for two new self-administration options | GSK
GSK today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab)
fda approvalfor two
https://nucalahcp.com/
Discover a Treatment Option | NUCALA (mepolizumab) for HCPs
Learn more about NUCALA (mepolizumab), a targeted biologic therapy approved for five indications. Hear from your peers, review patient profiles, and get dosing...
discovertreatmentoptionnucalamepolizumab
https://www.elsevier.es/en-revista-acta-otorrinolaringologica-espanola-402-articulo-evaluating-mepolizumab-dupilumab-for-severe-S2173573526000086
Evaluating mepolizumab and dupilumab for severe chronic rhinosinusitis with nasal polyps: insights...
IntroductionMonoclonal antibodies (mAbs) have been effective in managing chronic rhinosinusitis with